OTCPK:BTCY

Stock Analysis Report

Executive Summary

Biotricity, Inc., medical technology company, provides biometric data monitoring solutions in the United States.

Snowflake

Fundamentals

Worrying balance sheet with weak fundamentals.

Risks

  • Biotricity has significant price volatility in the past 3 months.
  • Biotricity is not covered by any analysts.

Share Price & News

How has Biotricity's share price performed over time and what events caused price changes?


Latest Share Price and Events


Market Performance


7 Day Return

-1.7%

BTCY

2.5%

US Healthcare Services

-0.6%

US Market


1 Year Return

-73.1%

BTCY

10.2%

US Healthcare Services

0.7%

US Market

BTCY underperformed the Healthcare Services industry which returned 10.3% over the past year.

BTCY underperformed the Market in United States of America which returned 0.6% over the past year.


Share holder returns

BTCYIndustryMarket
7 Day-1.7%2.5%-0.6%
30 Day4.5%-1.9%2.9%
90 Day-26.9%-2.9%1.3%
1 Year-73.1%-73.1%10.3%10.2%2.9%0.7%
3 Year-74.7%-74.7%51.7%51.4%44.6%35.2%
5 Yearn/a52.0%51.1%61.9%44.2%

Price Volatility Vs. Market

How volatile is Biotricity's share price compared to the market and industry in the last 5 years?


Simply Wall St News

No news available

Valuation

Is Biotricity undervalued based on future cash flows and its price relative to the stock market?


In this section, we usually try to help investors determine whether Biotricity is trading at an attractive price based on the cash flow it is expected to produce in the future. But as Biotricity has not provided consistent financial data, and the stock also has no analyst forecast or coverage, its intrinsic value cannot be reliably calculated by extrapolating past data or using analyst consensus cash flow predictions.

This is quite a rare situation as 89% of companies covered by Simply Wall St do have a valuation analysis.


Next Steps

  • Take a look at our analysis of BTCY’s management and see if the CEO’s compensation is within a reasonable range, who is on the board and if insiders have been trading lately.
  • When valuing a company like this, investors focus more on how they perceive the size of the opportunity, the company's ability to deliver and scale, and the strength of the team. While we are not analysing this type of data at the moment, if you don’t know where to start, we recommend reading through Biotricity regulatory filings here.
  • Explore potentially undervalued companies in the Healthcare industry.

Future Growth

How is Biotricity expected to perform in the next 1 to 3 years based on estimates from 0 analysts?

27.7%

Forecasted Healthcare industry annual growth in earnings


In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Biotricity has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Next Steps

  • Take a look at our analysis of BTCY’s management and see if the CEO’s compensation is within a reasonable range, who is on the board and if insiders have been trading lately.
  • While we do not consider unaudited financials to be a reliable enough to include in our analysis, you can access them on the OTC Markets Website. If you are looking for more of a qualitative research into the company, you can access Biotricity's filings and announcements here.
  • Explore growth companies in the Healthcare industry.

Past Performance

How has Biotricity performed over the past 5 years?

-21.1%

Historical annual earnings growth


Earnings and Revenue History


Past Earnings Growth Analysis

Biotricity does not make a profit and their year on year earnings growth rate was negative over the past 5 years.

Unable to compare Biotricity's 1-year earnings growth to the 5-year average as it is not currently profitable.

Unable to compare Biotricity's 1-year growth to the US Healthcare Services industry average as it is not currently profitable.


Return on Equity

It is difficult to establish if Biotricity has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) due to its liabilities exceeding its assets.


Return on Assets

It is difficult to establish if Biotricity has efficiently used its assets last year compared to the US Healthcare Services industry average (Return on Assets) as it is loss-making.


Return on Capital Employed

It is difficult to establish if Biotricity improved its use of capital last year versus 3 years ago (Return on Capital Employed) due to its liabilities exceeding its assets.


Next Steps

Financial Health

How is Biotricity's financial position?


Financial Position Analysis

Biotricity's short term (1 year) commitments are greater than its holdings of cash and other short term assets.

Biotricity's cash and other short term assets cover its long term commitments.


Debt to Equity History and Analysis

Biotricity has negative shareholder equity (liabilities exceed assets), this is a more serious situation compared with a high debt level.

Irrelevant to check if Biotricity's debt level has increased considering it has negative shareholder equity.


Balance Sheet

High level of physical assets or inventory.

Biotricity has negative shareholder equity (liabilities exceed assets) therefore debt is not covered by short term assets.


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Biotricity has less than a year of cash runway based on current free cash flow.

Biotricity has less than a year of cash runway if free cash flow continues to grow at historical rates of 26.8% each year.


Next Steps

Dividend

What is Biotricity's current dividend yield, its reliability and sustainability?


Dividend Yield and Payments Analysis

Unable to evaluate Biotricity's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.

Unable to evaluate Biotricity's dividend against the top 25% market benchmark as the company has not reported any payouts.

Unable to perform a dividend volatility check as Biotricity has not reported any payouts.

Unable to verify if Biotricity's dividend has been increasing as the company has not reported any payouts.


Current Payout to Shareholders

Unable to calculate sustainability of dividends as Biotricity has not reported any payouts.


Future Payout to Shareholders

Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.


Next Steps

Management

What is the CEO of Biotricity's salary, the management and board of directors tenure and is there insider trading?

1.9yrs

Average management tenure


CEO

Waqaas Al-Siddiq (34yo)

3.6yrs

Tenure

US$1,775,248

Compensation

Mr. Waqaas Al-Siddiq Founded Biotricity Inc. and has been its Chairman and Chief Executive Officer since February 2, 2016 and also serves as its President. Mr. Al-Siddiq founded iMedical and served as its  ...


CEO Compensation Analysis

Waqaas's remuneration is higher than average for companies of similar size in United States of America.

Waqaas's compensation has increased whilst company is loss making.


Management Age and Tenure

1.9yrs

Average Tenure

The average tenure for the Biotricity management team is less than 2 years, this suggests a new team.


Board Age and Tenure

3.3yrs

Average Tenure

55yo

Average Age

The tenure for the Biotricity board of directors is about average.


Insider Trading

No 3 month open market individual insider trading information.


Ownership Breakdown


Management Team

  • John Ayanoglou (53yo)

    Chief Financial Officer

    • Tenure: 1.9yrs
    • Compensation: US$312.84k
  • Casey Shattuck

    Global Vice President of Sales

    • Tenure: 1.5yrs
  • George Nikopoulos

    Director of Business Development

    • Tenure: 0yrs
  • Waqaas Al-Siddiq (34yo)

    Founder

    • Tenure: 3.6yrs
    • Compensation: US$1.78m
  • Amir Ali

    Chief Development Officer

    • Tenure: 0yrs

Board Members

  • Danny Sands

    Member of the Board of Advisors

    • Tenure: 3.3yrs
  • Norm Betts (65yo)

    Independent Director

    • Tenure: 3.4yrs
    • Compensation: US$39.98k
  • Reed Ferber

    Scientific & Medical Advisory Board

    • Tenure: 0yrs
  • Dave Rosa (55yo)

    Independent Director

    • Tenure: 3.3yrs
    • Compensation: US$39.98k
  • John Rother

    Member of the Board of Advisors

    • Tenure: 3.3yrs
  • Tom Nelson

    Member of the Board of Advisors

    • Tenure: 3.3yrs
  • Waqaas Al-Siddiq (34yo)

    Founder

    • Tenure: 3.6yrs
    • Compensation: US$1.78m
  • Patricia Kennedy

    Independent Director

    • Tenure: 0.8yrs
    • Compensation: US$12.70k
  • Buck Cross

    Member of Scientific & Medical Alliance Board

    • Tenure: 0.8yrs
  • Edward Lazaga

    Member of Scientific & Medical Alliance Board

    • Tenure: 0.8yrs

Company Information

Biotricity, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Biotricity, Inc.
  • Ticker: BTCY
  • Exchange: OTCPK
  • Founded:
  • Industry: Health Care Technology
  • Sector: Healthcare
  • Market Cap: US$20.464m
  • Shares outstanding: 35.90m
  • Website: https://www.biotricity.com

Number of Employees


Location

  • Biotricity, Inc.
  • 275 Shoreline Drive
  • Suite 150
  • Redwood City
  • California
  • 94065
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
BTCYOTCPK (Pink Sheets LLC)YesCommon StockUSUSDFeb 2016

Biography

Biotricity, Inc., medical technology company, provides biometric data monitoring solutions in the United States. The company focuses to deliver remote monitoring solutions to medical, healthcare, and consu ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/09/22 00:22
End of Day Share Price2019/09/20 00:00
Earnings2019/06/30
Annual Earnings2019/03/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.